Company intelligence / Profile preview

Birdie

Ownership: Private
Development stage: Commercial

Overview

Lead program in Phase I clinical trials, including a combination trial with Roche’s Tecentriq® (atezolizumab) targeting solid tumors. The company has built an IP portfolio around toll-like receptor modulators and focuses on novel cancer immunotherapies.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyImmunotherapy
Industry: Biotech

Partnerships

Taiwan Liposome Company Ltd. (“TLC”) – development/license agreement for nanomedicine-based immunotherapy productscollaboration with Roche for combination studies using Tecentriq® (atezolizumab)

Beyond the preview

Go deeper on Birdie.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Birdie.

Explore the full profile